Carbonyl-protein content increases in brain and blood of female rats after chronic oxycodone treatment.
Carbonyl-protein
Carbonylation
Cortex
Integrated stress response
Opioid
Oxidative stress
Oxycodone
Protein aggregates
Journal
BMC neuroscience
ISSN: 1471-2202
Titre abrégé: BMC Neurosci
Pays: England
ID NLM: 100966986
Informations de publication
Date de publication:
22 01 2020
22 01 2020
Historique:
received:
25
03
2019
accepted:
13
01
2020
entrez:
24
1
2020
pubmed:
24
1
2020
medline:
15
12
2020
Statut:
epublish
Résumé
Opioids are the most effective drugs commonly prescribed to treat pain. Due to their addictive nature, opioid pain relievers are now second to marijuana, ahead of cocaine with respect to dependence. Ours and other studies suggest potential toxic effects of chronic opioid administration leading to neuronal degeneration. It has been suggested that protein carbonylation may represent a sensitive biomarker of cellular degeneration. To evaluate whether prolonged oxycodone administration is associated with accumulation of protein aggregates that may contribute to neuronal degeneration we measured protein carbonylation levels in brain and also in blood plasma of rats after 30-days of 15 mg/kg daily oxycodone administration. We observed a significant increase in the level of carbonylated proteins in rat brain cortex after 30-days of oxycodone treatment compare to that in water treated animals. Also, oxycodone treated rats demonstrated accumulation of insoluble carbonyl-protein aggregates in blood plasma. Our data suggests that tests detecting insoluble carbonyl-protein aggregates in blood may serve as an inexpensive and minimally invasive method to monitor neuronal degeneration in patients with a history of chronic opioid use. Such methods could be used to detect toxic side effects of other medications and monitor progression of aging and neurodegenerative diseases.
Sections du résumé
BACKGROUND
Opioids are the most effective drugs commonly prescribed to treat pain. Due to their addictive nature, opioid pain relievers are now second to marijuana, ahead of cocaine with respect to dependence. Ours and other studies suggest potential toxic effects of chronic opioid administration leading to neuronal degeneration. It has been suggested that protein carbonylation may represent a sensitive biomarker of cellular degeneration. To evaluate whether prolonged oxycodone administration is associated with accumulation of protein aggregates that may contribute to neuronal degeneration we measured protein carbonylation levels in brain and also in blood plasma of rats after 30-days of 15 mg/kg daily oxycodone administration.
RESULTS
We observed a significant increase in the level of carbonylated proteins in rat brain cortex after 30-days of oxycodone treatment compare to that in water treated animals. Also, oxycodone treated rats demonstrated accumulation of insoluble carbonyl-protein aggregates in blood plasma.
CONCLUSIONS
Our data suggests that tests detecting insoluble carbonyl-protein aggregates in blood may serve as an inexpensive and minimally invasive method to monitor neuronal degeneration in patients with a history of chronic opioid use. Such methods could be used to detect toxic side effects of other medications and monitor progression of aging and neurodegenerative diseases.
Identifiants
pubmed: 31969118
doi: 10.1186/s12868-020-0552-2
pii: 10.1186/s12868-020-0552-2
pmc: PMC6977314
doi:
Substances chimiques
Analgesics, Opioid
0
Biomarkers
0
Oxycodone
CD35PMG570
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
4Références
ASN Neuro. 2013;5(1):e00111
pubmed: 23489322
Int J Clin Exp Pathol. 2015 Jul 01;8(7):8260-7
pubmed: 26339395
Neuroscience. 2010 Sep 15;169(4):1831-9
pubmed: 20600673
Free Radic Biol Med. 2002 May 1;32(9):790-6
pubmed: 11978480
J Neurosci. 2002 Sep 1;22(17):7650-61
pubmed: 12196588
Neuron. 2008 Dec 26;60(6):988-1009
pubmed: 19109907
EMBO J. 2005 Apr 6;24(7):1311-7
pubmed: 15775985
Genes Dev. 2004 Dec 15;18(24):3066-77
pubmed: 15601821
Nat Neurosci. 2013 Sep;16(9):1299-305
pubmed: 23933749
J Neurosci. 2010 Dec 15;30(50):16938-48
pubmed: 21159964
BBA Clin. 2015 Apr 30;4:1-6
pubmed: 26673529
J Clin Invest. 2002 Nov;110(10):1383-8
pubmed: 12438433
Psychopharmacology (Berl). 1991;105(1):101-6
pubmed: 1745703
BMC Neurosci. 2015 Sep 16;16:58
pubmed: 26377394
Nat Cell Biol. 2013 May;15(5):481-90
pubmed: 23624402
Brain. 2010 Jul;133(Pt 7):2098-114
pubmed: 20558415
J Clin Oncol. 2017 Dec 20;35(36):4042-4049
pubmed: 29048972
Int J Clin Exp Med. 2013 Aug 01;6(7):540-5
pubmed: 23936592
Neuroreport. 2002 Dec 20;13(18):2429-32
pubmed: 12499843
BMC Neurosci. 2018 Mar 23;19(1):15
pubmed: 29571287